Cell Care Therapeutics Raises $4.3 Million in Seed Funding

Source: Cell Care Therapeutics

Cell Care Therapeutics announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD).

Cell Care is pioneering the development of regenerative immunotherapy—a new therapeutic approach that has the potential to modulate the immune response in a way that leads to reduced inflammation, permits recovery, and promotes tissue remodeling. This therapy is derived from components that mesenchymal stem cells secrete, also known as their “secretome.” The secretome contains anti-inflammatory and pro-regenerative molecules that are anticipated to reverse and resolve inflammatory processes while stimulating tissue regeneration.

“The closing of this first round of financing is an endorsement of our novel approach of using stem cell secretions to modulate the immune system as an alternative to the more commercially challenging approach of using living cells to repair damaged tissue,” Nicolas Sohl, President and Chief Executive Officer of Cell Care, said in a company news release. “The ophthalmic community is embracing the theory that the treatment of complex degenerative diseases within the eye may require a broader set of signaling molecules that cannot be recapitulated by any single small molecule, RNA, or recombinant protein.”

“There remains an unmet medical need for patients suffering from retinal diseases. Many patients receive anti-VEGF therapies to treat symptoms, such as swelling from leaking blood vessels, without directly treating underlying inflammation or fibrosis,” Baruch D. Kuppermann, MD, PhD, director of UCI’s Gavin Herbert Eye Institute, said in the news release. “Cell Care’s innovative approach to applying regenerative immunotherapy to treat these challenging diseases potentially could provide an unique alternative to current therapies.”


Related Content